ReviewFrontiers in fungal biology2022
Burden Imposed by Heterologous Protein Production in Two Major Industrial Yeast Cell Factories: Identifying Sources and Mitigation Strategies.
Review in Frontiers in fungal biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Integrating dynamic modeling and continuous cultivation to enhance recombinant β-glucosidase production in Komagataella phaffii.Bioresources and bioprocessing · 2026Article
- Beyond monoculture limits: a critical review of yeast co-cultures for xylitol production from lignocellulosic biomass : Yeast co-cultures for xylitol production.World journal of microbiology & biotechnology · 2026Review
- Characterisation of metabolic burden in Pseudomonas putida reveals precursor limitation in heterologous lycopene production.Microbial cell factories · 2026Article
- Metabolic Footprint of Drosophila S2 Cells: Findings During the Production of a Recombinant Rabies Virus Glycoprotein.Biotechnology journal · 2026Article
- Article
- Regulatory and metabolic control of microbial biosynthetic gene clusters.Communications biology · 2026Review
- One Yeast, Sixteen Synthetic Chromosomes, Infinite Possibilities.Yeast (Chichester, England) · 2026Review
- Reintroduction of lignin-modifying enzymes in the brown-rot fungus Gloeophyllum trabeum restores ligninolytic activities but diminishes lignocellulose degradation.Fungal biology and biotechnology · 2026Article
- Targeted and quantitatively modeled biologic delivery via dual-functional probiotic yeast in inflammatory bowel disease.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- How far can you go? Extrapolating values of catalytic activity from known protein landscapes in natural and directed evolution.Chemical Society reviews · 2026Review
- Dual-channel optogenetics in yeast for multiplexed light-based control of cellular processes and pathways.Nature communications · 2026Article
- rDNA-mediated multicopy integration and gene dosage quantification system for microbial zeaxanthin biosynthesis.World journal of microbiology & biotechnology · 2026Article
- Yeast Stress Response to Synthetic Constructs.ACS synthetic biology · 2026Review
- Yeast as a Platform to Dissect Poly(ADP-Ribose) Polymerase Function fromInternational journal of molecular sciences · 2026Article
- Bacterial contamination in starch-to-ethanol fermentations: Can bacteriocin-producing Saccharomyces cerevisiae offer a solution?Journal of industrial microbiology & biotechnology · 2026Review
- Systems metabolic engineering of glutathione biosynthesis inEngineering microbiology · 2025Article
- Biosensor-driven strain engineering reveals key cellular processes for maximizing isoprenol production inScience advances · 2025Article
- Article
- Expression of Recombinant Hirudin in Bacteria and Yeast: A Comparative Approach.Methods and protocols · 2025Article
- Metabolic engineering of Saccharomyces cerevisiae for neoxanthin production.Microbial cell factories · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Production of heterologous proteins, especially biopharmaceuticals and industrial enzymes, in living cell factories consumes cellular resources. Such resources are reallocated from normal cellular processes toward production of the heterologous protein that is often of no benefit to the host cell. This competition for resources is a burden to host cells, has a negative impact on cell fitness, and may consequently trigger stress responses. Importantly, this often causes a reduction in final protein titers. Engineering strategies to generate more burden resilient production strains offer sustainable opportunities to increase production and profitability for this growing billion-dollar global industry. We review recently reported impacts of burden derived from resource competition in two commonly used protein-producing yeast cell factories:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.